Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 November 13, 2023 by Leave a Comment Last Updated on November 13, 2023 by [#item_full_content] Share this:TwitterFacebookMorePrintLike this:Like Loading... Related Spread the word
Leave a Reply